Heptagon Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-07-2024
- Paid Up Capital ₹ 0.10 M
as on 07-07-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.58 M
as on 07-07-2024
- Revenue 79.39%
(FY 2019)
- Profit 14.43%
(FY 2019)
- Ebitda 17.60%
(FY 2019)
- Net Worth -62.77%
(FY 2019)
- Total Assets -39.95%
(FY 2019)
About Heptagon Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.58 M.
Kannan Thirukumaran, Sebastian Durai, and Pushpanathan Wilson serve as directors at the Company.
- CIN/LLPIN
U74120TN2016PTC104911
- Company No.
104911
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Heptagon Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kannan Thirukumaran  | Director | 13-Jun-2019 | Current |
| Sebastian Durai | Director | 13-Jun-2019 | Current |
| Pushpanathan Wilson | Director | 24-Mar-2016 | Current |
Financial Performance of Heptagon Life Sciences.
Heptagon Life Sciences Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 79.39% increase. The company also saw a substantial improvement in profitability, with a 14.43% increase in profit. The company's net worth observed a substantial decline by a decrease of 62.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Heptagon Life Sciences?
In 2019, Heptagon Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 24 Jun 2020 | ₹0.58 M | Open |
Canara Bank Creation Date: 02 Mar 2018 | ₹3.00 M | Open |
How Many Employees Work at Heptagon Life Sciences?
Heptagon Life Sciences has a workforce of 5 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Heptagon Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Heptagon Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
